Enzo Biochem (ENZ)

[RonnieD]

They have zero debt, 76 million in cash and a mkt cap of only 150m (double their cash).

http://finance.yahoo.com/q/pr?s=ENZ

Enzo Biochem, Inc., a life sciences and biotechnology company, engages in research, development, manufacturing, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. The company operates in three segments: Life Sciences, Therapeutics, and Clinical Labs. The Life Sciences segment manufactures, develops, and markets biomedical research products and tools to research and pharmaceutical customers. It offers products applied in the fields of gene expression, non-radioactive labeling and detection, adipokines and obesity, apoptosis, bioactive lipids, cell cycle, cytoskeletal research, DNA damage and repair, epigenetics, immunology and cancer research, inflammation, neurobiology, nitric oxide and oxidative stress, and signal transduction. The Therapeutics segment engages in the research and development of various therapeutic drug candidates based on cell signaling, immune regulation, and gene therapy technologies for the treatment of gastrointestinal, infectious, ophthalmic, and metabolic diseases. The Clinical Labs segment offers routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, and search for an otherwise undiagnosed condition. It also operates a full-service clinical laboratory, a network of 23 patient service centers, a stand alone or rapid response laboratory, and a full-service phlebotomy department. Enzo Biochem sells its products through direct sales force and distributors in the United States, Switzerland, the United Kingdom, and internationally. The company was founded in 1976 and is headquartered in New York, New York.